A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01083615 |
|
Recruitment Status :
Terminated
(Unable to enroll due to criteria for stable baseline pain)
First Posted : March 10, 2010
Last Update Posted : October 12, 2016
|
Sponsor:
Achieve Life Sciences
Collaborator:
Teva Pharmaceuticals USA
Information provided by (Responsible Party):
Achieve Life Sciences
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Terminated |
|---|---|
| Actual Primary Completion Date : | March 2013 |
| Actual Study Completion Date : | March 2013 |
| Certification/Extension First Submitted : | November 4, 2015 |